

PharmLabs San Diego Certificate of Analysis

3421 Hancock St, Second Floor, San Diego, CA 92110 | License: C8-000098-LIC
 ISO/IEC 17025:2017 Acc. L17-427-1 #85368



Sample **Hidden Hills Limey Znow Conez 2G Disposable**

| | |
|--------------------------------|--|
| Sample ID SD231212-075 (88381) | Matrix Concentrate (Inhalable Cannabis Good) |
| Tested for Midnight MFG | |
| Sampled - | Received Dec 12, 2023 |
| Analyses executed CANX, QARUSH | Reported Dec 14, 2023 |

CANX - Cannabinoids Analysis

Analyzed Dec 14, 2023 | Instrument HPLC-VWD | Method SOP-001
 The expanded Uncertainty of the Cannabinoid analysis is approximately 7.806% at the 95% Confidence Level

| Analyte | LOD mg/g | LOQ mg/g | Result % | Result mg/g |
|--|----------|----------|----------|-------------|
| 11-Hydroxy-Δ8-Tetrahydrocannabinarin (11-Hyd-Δ8-THCV) | 0.013 | 0.041 | ND | ND |
| Cannabidiolcin (CBDO) | 0.002 | 0.007 | ND | ND |
| Abnormal Cannabidiolcin (a-CBDO) | 0.01 | 0.031 | ND | ND |
| (+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC) | 0.012 | 0.036 | ND | ND |
| 11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC) | 0.007 | 0.021 | ND | ND |
| Cannabidiolic Acid (CBDA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol Acid (CBGA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol (CBG) | 0.001 | 0.16 | ND | ND |
| Cannabidiol (CBD) | 0.001 | 0.16 | ND | ND |
| 1(S)-THD (s-THD) | 0.013 | 0.041 | ND | ND |
| 1(R)-THD (r-THD) | 0.025 | 0.075 | ND | ND |
| Tetrahydrocannabinarin (THCV) | 0.001 | 0.16 | ND | ND |
| Δ8-tetrahydrocannabinarin (Δ8-THCV) | 0.021 | 0.064 | ND | ND |
| Cannabidihexol (CBDH) | 0.005 | 0.16 | ND | ND |
| Tetrahydrocannabinol (Δ9-THCB) | 0.013 | 0.038 | ND | ND |
| Cannabinol (CBN) | 0.001 | 0.16 | 1.47 | 14.66 |
| Cannabidiophorol (CBDP) | 0.015 | 0.047 | ND | ND |
| exo-THC (exo-THC) | 0.005 | 0.16 | ND | ND |
| Tetrahydrocannabinol (Δ9-THC) | 0.003 | 0.16 | ND | ND |
| Δ8-tetrahydrocannabinol (Δ8-THC) | 0.004 | 0.16 | 65.36 | 653.62 |
| (6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10) | 0.015 | 0.16 | ND | ND |
| Hexahydrocannabinol (S Isomer) (9s-HHC) | 0.017 | 0.16 | ND | ND |
| (6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10) | 0.007 | 0.16 | ND | ND |
| Hexahydrocannabinol (R Isomer) (9r-HHC) | 0.016 | 0.16 | ND | ND |
| Tetrahydrocannabinolic Acid (THCA) | 0.001 | 0.16 | 0.16 | 1.57 |
| Δ9-Tetrahydrocannabinol (Δ9-THCH) | 0.024 | 0.071 | ND | ND |
| Cannabinol Acetate (CBNO) | 0.014 | 0.043 | ND | ND |
| Δ9-Tetrahydrocannabinophorol (Δ9-THCP) | 0.017 | 0.16 | 16.27 | 162.66 |
| Δ8-Tetrahydrocannabinophorol (Δ8-THCP) | 0.041 | 0.16 | ND | ND |
| Cannabicitran (CBT) | 0.005 | 0.16 | ND | ND |
| Δ8-THC-O-acetate (Δ8-THCO) | 0.076 | 0.16 | ND | ND |
| 9(S)-HHCP (s-HHCP) | 0.031 | 0.094 | ND | ND |
| Δ9-THC-O-acetate (Δ9-THCO) | 0.066 | 0.16 | ND | ND |
| 9(R)-HHCP (r-HHCP) | 0.026 | 0.079 | ND | ND |
| 9(S)-HHC-O-acetate (s-HHCO) | 0.005 | 0.16 | ND | ND |
| 9(R)-HHC-O-acetate (r-HHCO) | 0.008 | 0.025 | ND | ND |
| 3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8) | 0.067 | 0.204 | ND | ND |
| Total THC (THCa * 0.877 + Δ9THC) | | | 0.14 | 1.38 |
| Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC) | | | 65.50 | 655.00 |
| Total CBD (CBDA * 0.877 + CBD) | | | ND | ND |
| Total CBG (CBGa * 0.877 + CBG) | | | ND | ND |
| Total HHC (9r-HHC + 9s-HHC) | | | ND | ND |
| Total Cannabinoids | | | 85.23 | 852.32 |

Sample photography



UJ Unidentified
 ND Not Detected
 N/A Not Applicable
 NT Not Reported
 LOD Limit of Detection
 LOQ Limit of Quantification
 <LOQ Detected
 >ULOL Above upper limit of linearity
 CFU/g Colony Forming Units per 1 gram
 TNTC Too Numerous to Count



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager
 Thu, 14 Dec 2023 12:48:31 -0800

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. L17-427-1

*This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evaluation unless explicitly required by federal, state or local laws and has been reported on the certificate of analysis. Measurement of uncertainty is available upon request.